Madhok T C, Chao C C, Matta S G, Hong A, Sharp B M
Endocrine-Neuroscience Laboratory, Minneapolis Medical Research Foundation, MN.
Biochem Biophys Res Commun. 1989 Nov 30;165(1):151-7. doi: 10.1016/0006-291x(89)91047-4.
Polyclonal antibodies were raised against a synthetic decapeptide (designated S3) predicted from a segment of the alpha-3 subunit cDNA (amino acid residues 130-139) encoding the rat brain nicotinic cholinergic receptor. This segment was selected because it may be proximate to the nicotine/acetylcholine-binding site of the receptor (1). By radioligand binding assays and sucrose density gradient centrifugation, these monospecific antibodies were shown to inhibit the binding of [3H]nicotine to both the large molecular weight rat brain receptor (240 kDa) and to an SDS-disaggregated nicotine-binding subunit species (80 kDa), in a dose-dependent manner. The neutralizing effect of the anti-S3 antibodies supports the view that this region of the protein is closely related to the agonist binding site.